Publications by authors named "Michael Merger"

Claim this Profile
F
Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer.
Isabelle Ray-Coquard, David Cibula, Mansoor R Mirza, Alexander Reuss, Caterina Ricci, Michael Merger

Int J Cancer· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
Andreas du Bois, Gunnar Kristensen, Isabelle Ray-Coquard, Alexander Reuss, Sandro Pignata, Michael Merger

Lancet Oncol· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase II study of nintedanib in metastatic castration-resistant prostate cancer postdocetaxel.
Jean-Pierre Droz, Jaques Medioni, Christine Chevreau, Helene De Mont-Serrat, Michael Merger

Anticancer Drugs· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prolonged response of relapsed high grade serous ovarian carcinoma to the oral angiokinase inhibitor nintedanib in a patient with a germline BRCA1 mutation.
Han Hsi Wong, Christine Parkinson, Jonathan A Ledermann, James D Brenton, Michael Merger

Gynecol Oncol Case Rep· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.
Jonathan A Ledermann, Allan Hackshaw, Stan Kaye, Gordon Jayson, Hani Gabra, Michael Merger

J Clin Oncol· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancer.
Olivier Bouche, Frederique Maindrault-Goebel, Michel Ducreux, Gerard Lledo, Thierry Andre, Michael Merger

Anticancer Res· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prolactin stimulates proliferation of the glucose-dependent beta-cell line INS-1 via different IRS-proteins.
Sigrun R Hügl, Michael Merger

JOP· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis